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Background: Symptoms of gastro-esophageal reflux disease (GERD) in pregnancy are reported with a prevalence
of 30–80%. The aim of this study was to assess the prevalence and severity of GERD symptoms during the course of
pregnancy. Furthermore current practice in medical care for GERD during pregnancy was assessed.
Methods: We performed a prospective longitudinal cohort study on 510 pregnant women (mean age 28.12, SD
5.3). Investigations for reflux symptoms where based on the use of validated reflux-disease questionnaire (RDQ).
Additional information was collected about the therapy. A group of non-pregnant women (mean age 24.56, SD 5.7)
was included as controls. Frequency and severity of reflux symptoms were recorded in each trimester of pregnancy.
Results: The prevalence of GERD symptoms in pregnant women increased from the first trimester with 26.1 to
36.1% in the second trimester and to 51.2% in the third trimester of pregnancy. The prevalence of GERD symptoms
in the control group was 9.3%.
Pregnant women received medication for their GERD symptoms in 12.8% during the first, 9.1% during the second
and 15.7% during the third trimester. Medications used >90% antacids, 0% PPI.
Conclusion: GERD symptoms occur more often in pregnant women than in non-pregnant and the frequency
rises in the course of pregnancy. Medical therapy is used in a minority of cases and often with no adequate
symptom relief.
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Gastro-esophageal reflux disease (GERD) is the most fre-
quent acid-related disease as of today and occurs at all
ages from childhood to advanced age [1-3]. Pregnancy
has long been recognized as a condition that predisposes
to GERD and GERD symptoms are known to be common
in pregnant women [4,5]. Studies that have addressed the
issue of GERD symptoms in pregnancy reported a preva-
lence between 30 and 80% [6-12]. We have previously
reported a prevalence of GERD-related symptoms of
56.3%, in the third trimester of pregnancy [9].* Correspondence: saramalfertheiner@googlemail.com
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distribution, and reproduction in any mediumThe presentation of typical GERD symptoms during
pregnancy is comparable with the adult population in
general [13]. Heartburn and regurgitation are the most
frequent symptoms [6,14]. The majority of pregnant
GERD sufferers report exacerbation of symptoms after
eating and at bedtime [15,16]. We have previously shown
the negative impact of GERD symptoms on the quality
of life in pregnant women and the insufficient therapy
for symptom relief in late pregnancy [9].
Aim of this study was to assess the nature and preva-
lence of reflux symptoms in the course of pregnancy.
This is the first study on GERD symptoms using vali-
dated questionnaires and using the new definition of
GERD based on the Montreal criteria from 2006 which
defined GERD as a condition which develops when
the reflux of stomach contents causes troublesomed Central Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Flowchart of participants across the study. * 54 missing
RDQ 1. Trimester, 9 missing RDQ 2. +3. Trimester, 4 missing RDQ 2.
Trimester, 19 missing RDQ 3. Trimester.
Table 1 Demographic data
Variables Pregnant Non-pregnant p-value
Number of patients 408 305
Mean age (years) (SD) 28.12 (5.3) 24.56 (5.7) < 0.0001
Mean weight (SD) 66.3 (13.9) 62.2 (9.8) <0.0001
Mean height (SD) 167.0 (6,3) 167.7 (6.6) 0.189
Mean BMI (SD) 23,74 (4,5) 22,12 (3,2) <0.0001
Smokers 19.8% 22.2% 0.499
Coffee consumer 68.3% 65.4% 0.458
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diagnosis on the basis of reflux symptoms [17].
Methods
We conducted a prospective longitudinal cohort study to
investigate the prevalence of GERD symptoms during
the time course of pregnancy by using validated reflux-
disease questionnaires and further gather information
about the treatment patients receive.
Subjects
Five hundred ten consecutive pregnant women in the
first trimester of pregnancy and three hundred thirty
non-pregnant women were recruited to participate in the
study. All women were given two questionnaires: the
validated German version of the Reflux Disease Ques-
tionnaire (RDQ) [18] and a self-administered question-
naire. The pregnant women were followed up and
repeated to fill out the RDQ in the second and third tri-
mester of pregnancy. Pregnant women were recruited
from the University clinic and private clinics in and
around Magdeburg, Germany (population approximately
300 000 people), the group of non pregnant women was
recruited at the University campus and in the city of
Magdeburg. The study was approved by the ethics com-
mittee of the University of Magdeburg and conducted
based on the guidelines of the Helsinki declaration.
Definition
The diagnosis of symptomatic GERD was made accord-
ing to the Montreal criteria 2006, where GERD is defined
as a condition which develops when the reflux of stom-
ach contents causes troublesome symptoms and/or com-
plications [17]. Mild symptoms occurring 2 or more days
a week, or moderate/severe symptoms occurring more
than 1 day a week are often considered troublesome by
patients [17].
Extra-esophageal symptoms were not considered for
the diagnosis of GERD in our population because of lack
of specificity.
Questionnaires
The RDQ comprises 12 questions; six are related to
symptom frequency and six to symptom severity occur-
ring during the previous week [18]. Symptoms evaluated
in the RDQ were: burning behind the breastbone, pain
behind the breastbone, upper stomach burning, upper
stomach pain, acid taste in the mouth and regurgitation.
Symptom frequency and severity were measured on six-
point scales; from no occurrence to daily, and from
none to very severe, respectively. GERD was diagnosed
according to the definition mentioned above.
In the self-administered questionnaire, age, weight before
pregnancy, height, parity, medication intake (includingprescribed or over-the-counter use of antacids), add-
itional diseases, working status, level of education and
consumption of caffeine, tobacco and alcohol were
recorded for each patient. BMI was based on the height
and weight before pregnancy. Additionally, questions were
given about the patient’s GERD symptoms before preg-
nancy as well as the patient’s mother’s history in relation
to GERD during her pregnancy and chronic heartburn. Ex-
clusion criteria included operations or malformations
of the gastrointestinal tract, chronic inflammatory bowel
diseases and high-risk pregnancies.
Statistical analysis
Results are expressed as mean, unless otherwise indi-
cated. All data was processed with the statistical analysis
program SAS (Cary, NC, USA). P-values were calculated
using Unpaired t-test or Fishers exact test as indicated.
Results
Demographic characteristics
A total of 840 (510 pregnant) women were recruited and
returned written informed consent, Figure 1 shows the
flow of participants across the study. Seven hundred thir-
teen women were finally included, 408 pregnant and 305
Table 2 Frequency of symptoms (all values given in %)
Symptom Burning behind breastbone Pain behind breastbone Upper stomach burning Upper stomach pain Acid taste in mouth Regurgitation
None 82,8 71,4 55,8 96,1 89,5 83,6 77,4 92,4 85,1 79,2 68,7 94,8 89,7 82,8 75,5 83,4 75,9 69,1 53,1 84,6 73,4 66,0 48,2 82,6
<1x/week 4,5 7,1 8,9 2,3 6,0 7,2 8,2 5,3 5,7 5,9 7,7 3,9 5,3 7,3 7,5 9,9 7,2 8,2 9,8 10,2 9,5 9,1 11,1 13,8
>1x/week 2,7 6,9 8,6 0,7 1,7 3,0 5,7 1,3 2,7 4,7 6,5 1,0 2,8 3,0 7,3 4,3 5,5 7,2 8,8 3,3 5,2 8,1 10,3 2,3
2–3x/week 7,2 7,1 10,6 1,0 2,0 3,5 3,5 0,0 4,0 6,4 7,9 0,3 1,8 4,5 6,3 1,3 7,2 8,4 13,0 1,3 5,2 10,8 12,0 1,3
4–5x/week 0,5 3,0 5,9 0,0 0,2 0,5 1,7 0,7 1,7 1,5 3,2 0,0 0,5 1,0 1,0 0,7 1,7 2,0 7,6 0,3 3,5 3,0 8,4 0,0
Daily 2,2 4,4 10,1 0,0 0,5 2,2 3,5 0,3 0,7 2,2 6,0 0,0 0,0 1,5 2,5 0,3 2,5 5,2 7,6 0,0 3,2 3,0 10,1 0,0



















Table 3 Severity of symptoms (all values given in %)
Symptom Burning behind breastbone Pain behind breastbone Upper stomach burning Upper stomach pain Acid taste in mouth Regurgitation
None 86,6 75,5 57,7 96,8 91,8 85,5 80,1 94,0 88,0 81,7 71,4 96,5 90,4 84,0 78,7 86,5 80,2 73,6 55,4 85,5 77,7 70,3 51,6 85,2
Very mild 2,2 4,3 7,0 1,1 3,0 5,5 4,9 2,5 3,3 4,4 3,8 2,1 3,8 5,2 6,8 3,5 4,1 5,4 7,5 7,1 3,8 6,0 7,3 7,8
Mild 1,6 4,9 6,0 0,7 1,6 2,5 4,6 1,8 2,2 3,0 5,4 0,4 2,5 1,7 2,7 4,6 4,6 4,3 8,1 4,3 4,9 6,8 8,1 4,6
Moderate 3,8 6,0 11,7 1,1 2,2 3,6 5,2 1,4 2,2 5,7 7,1 1,1 2,2 5,5 4,9 4,6 6,8 8,2 10,8 3,2 6,0 7,1 15,9 1,4
Severe 3,5 4,9 8,4 0,4 0,8 1,4 1,6 0,4 3,0 3,0 6,0 0,0 0,8 2,2 4,4 0,7 2,4 4,6 11,8 0,0 3,5 4,9 7,8 1,1
Very severe 2,2 4,3 9,2 0,0 0,5 1,6 3,5 0,0 1,4 2,2 6,3 0,0 0,3 1,4 2,5 0,0 1,9 3,8 6,5 0,0 4,1 4,9 9,4 0,0



















Figure 2 Prevalence of GERD in the trimesters of pregnancy
and a non-pregnant control group (values given in percent %).
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14 to 43 years (mean 28.12 ± 5.3), in the non pregnant
women from 17 to 47 years (mean 24.56±5.7). BMI ranged
from 15.8 to 41.3 (mean 23,74±4,5) in pregnant women
and from 16.8 to 36.4 (mean 22.12 ±3.2) in non pregnant
women. 61.3% of the pregnant were primipara, in the group
of non-pregnant women 16.1% have been pregnant before.
Patient demographics are shown in Table 1.
GERD symptoms
The most frequent symptoms in pregnant and non-
pregnant women were acid taste in mouth and regurgita-
tion. In the third trimester of pregnancy 40.7% suffered
from regurgitation at least once a week. Regurgitation
occurred in 3.6% of non-pregnant women more than
once a week. Of the pregnant women 12.5% had heart-
burn at least once a week during their first trimester,
21.5% during the second and 35.3% during the third
trimester of pregnancy. Heartburn al least once a week
was experienced by 1.6% of non pregnant women.
Daily heartburn occurred in 10.1% of women in the
third trimester.Table 4 Medications taken for reflux symptoms during pregn
Medications
Calcium carbonate, Magnesium carbonate (RennieW)
Magaldrate (RiopanW, MagaldratW)
Algedrate, magnesium hydroxide (MaaloxanW)
Hydrotalcide (TalcidW)
Almasilate (SimagelW)
Sodium bicarbonate (Bullrich SalzW)
Sodium bicarbonate, Calcium carbonate, alginic acid (GavisconW)
Ranitidine (RaniticW)
All values are given in percent, brand names are given in brackets.Every symptom recorded occurred significantly more
often in pregnant than in non-pregnant women (Table 2).
And the frequency of all individual symptoms increased
significantly from one trimester to the next and pre-
sented the highest frequency in the third trimester
(Table 2).
Regarding the severity of the symptoms beside acid
taste in mouth and regurgitation also a burning sensa-
tion behind the breastbone were symptoms perceived as
most bothersome (Table 3). Acid taste in mouth was
reported as severe or very severe in 4.3%, 8.4% and
18.3% from the first to the third trimester respectively.
The severity of symptoms was significantly higher in
pregnant than in non-pregnant women and increased
steadily during the course of pregnancy (Table 3). At
least one symptom was experienced severe or very
severe by 29.2% of women in the third trimester com-
pared to 13.2% in the second and 11.3% in the first tri-
mester. The prevalence and severity of the symptoms is
shown in detail in Tables 2 and 3.
GERD diagnosis
The diagnosis of GERD was based on typical reflux
symptoms, either mild symptoms occurring two or more
days a week, or moderate/severe symptoms occurring
more than one day a week. Symptoms referring to upper
stomach pain and upper stomach burning recorded with
the RDQ as well were excluded for GERD diagnosis as
they are considered to be nonspecific for GERD [18].
The symptom based diagnosis of GERD found a preva-
lence of 26.1% in the first trimester, 36.1% in the second
trimester and 51.2% in the third trimester of pregnancy
(Figure 2). In non pregnant women the prevalence of
GERD was 9.3%.
GERD therapy
The use of medication for neutralizing or suppressing
gastric acid was recorded with a self administered ques-
tionnaire. In the first trimester of pregnancy 12.8% of
women reported to use acid neutralizing medications, in
the second trimester 9.1% and in the third 15.7%. In theancy
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antagonist, all others utilized antacids, none received
PPI. The distribution of used medications during preg-
nancy is shown in Table 4. In the group of non-pregnant
women 3.3% reported intake of antacids and PPI. GERD
symptoms in pregnant women on antacids increased
during pregnancy in the same magnitude as in those
with no medication. The evolution of heartburn and
regurgitation is shown in Table 5.
While using antacids 14.29% of women reported regur-
gitation as very severe, these women continued the
intake of antacids throughout their pregnancy and 37.5%
of them reported regurgitation as very severe in the
third trimester.
Discussion
GERD symptoms are very frequent in pregnant women
and they increase in severity during the course of preg-
nancy. The novelty of our study is the methodology
employed for the assessment of symptoms. The study is
the largest longitudinal study using validated question-
naires to asses GERD symptoms in pregnant women.
The overall prevalence of 26,1%; 36,1% and 51,2% in the
trimesters of pregnancy display the magnitude of the
problem and is in accordance and extends the results of
previous studies [6,10-12]. The pathophysiologic mechan-
isms involved in the abnormal gastric reflux during preg-
nancy are decreased lower esophageal sphincter pressure
and alteration in gastrointestinal transit due to hormone
changes, and increased intra-abdominal pressure second-
ary to the enlarged gravid uterus [4,19].
GERD impairs the quality of life, and the negative im-
pact is felt as a severe threat when symptoms are experi-
enced severe or very severe. An aspect of importance is
that more than every third woman suffers from severe
GERD symptoms during pregnancy, but not even every
fifth woman with symptoms receives acid neutralizing/
suppressive medication. There is good reason for the
cautions use of medical therapy during pregnancy be-
cause of the fear of having side effects for the unborn life
at the back of one’s mind. Though we do not exactly
know how influencing the untreated suffering of theTable 5 Frequency and severity of regurgitation in
patients receiving Antacids in all trimesters of pregnancy
Frequency 1T. 2T. 3T. Severity 1T. 2T. 3T.
None 27,3 13,0 17,4 None 28,57 12,50 0,0
<1x/week 27,3 17,4 8,7 Very mild 14,29 25,00 12,50
>1x/week 18,2 43,5 34,8 Mild 28,57 12,50 25,00
2–3x/week 13,6 13,0 17,4 Moderate 14,29 25,00 12,50
4–5x/week 9,1 8,7 4,3 Severe 0,0 12,50 12,50
Daily 4,5 4,3 17,4 Very severe 14,29 12,50 37,50
n= 23 (all values given in %).mothers is. The standard medication for GERD in the
non-pregnant population is proton pump inhibitors
(PPIs) which were shown to be effective and well toler-
ated. In contrast to the non-pregnant population a step-
up algorithm is recommended during pregnancy [5].
There is prospective data on PPIs taken during the first
trimester of pregnancy, that showed no increased risk of
major birth defects [20]. PPIs can be considered as safe
drugs during pregnancy [21,22]. In most pregnant
women reflux symptoms can be managed by lifestyle
modifications and intermittent use of antacids. However
in women with severe symptoms PPIs should be the
treatment of choice as they are most effective with no
safety concerns. Omeprazole is the best studied PPI in
pregnancy [22].
Conclusion
Every second women suffers from GERD during preg-
nancy. Heartburn, regurgitation, and acid taste in mouth
are bothersome symptoms affecting the women’s quality
of life. Not even half of the women with severe or very
severe symptoms are treated adequately. Our data and
the last publications on safety of PPIs during pregnancy
should be implemented in novel recommendations for
GERD therapy during pregnancy.
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